Trials / Unknown
UnknownNCT05949775
Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
Clinical Study on the Treatment of Advanced Malignant Solid Tumors With the Combination of mRNA
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Stemirna Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open, single arm, dose increasing study to evaluate the safety and efficacy of the combination of mRNA personalized tumor vaccine encoding neoantigen (hereinafter referred to as tumor vaccine) and Sintilimab injection (hereinafter referred to as Sintilimab) in the treatment of advanced malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Neoantigen mRNA Personalised Cancer vaccine | Drug: Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab Injection Subcutaneous Injection |
Timeline
- Start date
- 2023-07-20
- Primary completion
- 2025-12-12
- Completion
- 2026-03-20
- First posted
- 2023-07-18
- Last updated
- 2023-07-18
Source: ClinicalTrials.gov record NCT05949775. Inclusion in this directory is not an endorsement.